BACKGROUND: In patients with acquired aplastic anemia, destruction of hematopoietic cells by the immune system leads to pancytopenia. Patients have a response to immunosuppressive therapy, but myelodysplastic syndromes and acute myeloid leukemia develop in about 15% of the patients, usually many months to years after the diagnosis of aplastic anemia. METHODS: We performed next-generation sequencing and array-based karyotyping using 668 blood samples obtained from 439 patients with aplastic anemia. We analyzed serial samples obtained from 82 patients. RESULTS: Somatic mutations in myeloid cancer candidate genes were present in one third of the patients, in a limited number of genes and at low initial variant allele frequency. Clonal hematopoiesis was detected in 47% of the patients, most frequently as acquired mutations. The prevalence of the mutations increased with age, and mutations had an age-related signature. DNMT3A-mutated and ASXL1-mutated clones tended to increase in size over time; the size of BCOR- and BCORL1-mutated and PIGA-mutated clones decreased or remained stable. Mutations in PIGA and BCOR and BCORL1 correlated with a better response to immunosuppressive therapy and longer and a higher rate of overall and progression-free survival; mutations in a subgroup of genes that included DNMT3A and ASXL1 were associated with worse outcomes. However, clonal dynamics were highly variable and might not necessarily have predicted the response to therapy and long-term survival among individual patients. CONCLUSIONS: Clonal hematopoiesis was prevalent in aplastic anemia. Some mutations were related to clinical outcomes. A highly biased set of mutations is evidence of Darwinian selection in the failed bone marrow environment. The pattern of somatic clones in individual patients over time was variable and frequently unpredictable. (Funded by Grant-in-Aid for Scientific Research and others.).
BACKGROUND: In patients with acquired aplastic anemia, destruction of hematopoietic cells by the immune system leads to pancytopenia. Patients have a response to immunosuppressive therapy, but myelodysplastic syndromes and acute myeloid leukemia develop in about 15% of the patients, usually many months to years after the diagnosis of aplastic anemia. METHODS: We performed next-generation sequencing and array-based karyotyping using 668 blood samples obtained from 439 patients with aplastic anemia. We analyzed serial samples obtained from 82 patients. RESULTS: Somatic mutations in myeloid cancer candidate genes were present in one third of the patients, in a limited number of genes and at low initial variant allele frequency. Clonal hematopoiesis was detected in 47% of the patients, most frequently as acquired mutations. The prevalence of the mutations increased with age, and mutations had an age-related signature. DNMT3A-mutated and ASXL1-mutated clones tended to increase in size over time; the size of BCOR- and BCORL1-mutated and PIGA-mutated clones decreased or remained stable. Mutations in PIGA and BCOR and BCORL1 correlated with a better response to immunosuppressive therapy and longer and a higher rate of overall and progression-free survival; mutations in a subgroup of genes that included DNMT3A and ASXL1 were associated with worse outcomes. However, clonal dynamics were highly variable and might not necessarily have predicted the response to therapy and long-term survival among individual patients. CONCLUSIONS:Clonal hematopoiesis was prevalent in aplastic anemia. Some mutations were related to clinical outcomes. A highly biased set of mutations is evidence of Darwinian selection in the failed bone marrow environment. The pattern of somatic clones in individual patients over time was variable and frequently unpredictable. (Funded by Grant-in-Aid for Scientific Research and others.).
Authors: John S Welch; Timothy J Ley; Daniel C Link; Christopher A Miller; David E Larson; Daniel C Koboldt; Lukas D Wartman; Tamara L Lamprecht; Fulu Liu; Jun Xia; Cyriac Kandoth; Robert S Fulton; Michael D McLellan; David J Dooling; John W Wallis; Ken Chen; Christopher C Harris; Heather K Schmidt; Joelle M Kalicki-Veizer; Charles Lu; Qunyuan Zhang; Ling Lin; Michelle D O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Lucinda A Fulton; Vincent J Magrini; Sean D McGrath; Ryan T Demeter; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd N Wylie; Jason R Walker; Mark A Watson; Sharon E Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Jacqueline E Payton; Jack D Baty; Shashikant Kulkarni; Jeffery M Klco; Michael H Tomasson; Peter Westervelt; Matthew J Walter; Timothy A Graubert; John F DiPersio; Li Ding; Elaine R Mardis; Richard K Wilson Journal: Cell Date: 2012-07-20 Impact factor: 41.582
Authors: Phillip Scheinberg; James N Cooper; Elaine M Sloand; Colin O Wu; Rodrigo T Calado; Neal S Young Journal: JAMA Date: 2010-09-22 Impact factor: 56.272
Authors: A A Lane; O Odejide; N Kopp; S Kim; A Yoda; R Erlich; N Wagle; G A Abel; S J Rodig; J H Antin; D M Weinstock Journal: Leukemia Date: 2013-02-01 Impact factor: 11.528
Authors: Lucia Gargiulo; Maria Papaioannou; Michela Sica; Giulia Talini; Aristeidis Chaidos; Barbara Richichi; Andrei V Nikolaev; Cristina Nativi; Mark Layton; Josu de la Fuente; Irene Roberts; Lucio Luzzatto; Rosario Notaro; Anastasios Karadimitris Journal: Blood Date: 2013-01-31 Impact factor: 22.113
Authors: T Yasuda; T Ueno; K Fukumura; A Yamato; M Ando; H Yamaguchi; M Soda; M Kawazu; E Sai; Y Yamashita; M Murata; H Kiyoi; T Naoe; H Mano Journal: Leukemia Date: 2013-09-26 Impact factor: 12.883
Authors: Mingchao Xie; Charles Lu; Jiayin Wang; Michael D McLellan; Kimberly J Johnson; Michael C Wendl; Joshua F McMichael; Heather K Schmidt; Venkata Yellapantula; Christopher A Miller; Bradley A Ozenberger; John S Welch; Daniel C Link; Matthew J Walter; Elaine R Mardis; John F Dipersio; Feng Chen; Richard K Wilson; Timothy J Ley; Li Ding Journal: Nat Med Date: 2014-10-19 Impact factor: 53.440
Authors: Cathy C Laurie; Cecelia A Laurie; Kenneth Rice; Kimberly F Doheny; Leila R Zelnick; Caitlin P McHugh; Hua Ling; Kurt N Hetrick; Elizabeth W Pugh; Chris Amos; Qingyi Wei; Li-e Wang; Jeffrey E Lee; Kathleen C Barnes; Nadia N Hansel; Rasika Mathias; Denise Daley; Terri H Beaty; Alan F Scott; Ingo Ruczinski; Rob B Scharpf; Laura J Bierut; Sarah M Hartz; Maria Teresa Landi; Neal D Freedman; Lynn R Goldin; David Ginsburg; Jun Li; Karl C Desch; Sara S Strom; William J Blot; Lisa B Signorello; Sue A Ingles; Stephen J Chanock; Sonja I Berndt; Loic Le Marchand; Brian E Henderson; Kristine R Monroe; John A Heit; Mariza de Andrade; Sebastian M Armasu; Cynthia Regnier; William L Lowe; M Geoffrey Hayes; Mary L Marazita; Eleanor Feingold; Jeffrey C Murray; Mads Melbye; Bjarke Feenstra; Jae H Kang; Janey L Wiggs; Gail P Jarvik; Andrew N McDavid; Venkatraman E Seshan; Daniel B Mirel; Andrew Crenshaw; Nataliya Sharopova; Anastasia Wise; Jess Shen; David R Crosslin; David M Levine; Xiuwen Zheng; Jenna I Udren; Siiri Bennett; Sarah C Nelson; Stephanie M Gogarten; Matthew P Conomos; Patrick Heagerty; Teri Manolio; Louis R Pasquale; Christopher A Haiman; Neil Caporaso; Bruce S Weir Journal: Nat Genet Date: 2012-05-06 Impact factor: 38.330